Advanced

Blodplasma används som läkemedel. Men nationella, evidensbaserade behandlingsriktlinjer saknas

Palmblad, J; Johnsson, H; Lagerkranser, M; Sundelin, G; Wikman, A and Schött, Ulf LU (2008) In Läkartidningen p.26-30
Abstract
There are great regional variations in the use of plasma products. Evidence-based guidelines for plasma treatment are lacking. The Swedish market offers a non-commercial plasma product, produced by the hospital-based transfusion departments. There is also the commercial, virus-inactivated “SD plasma”. This is more expensive than the non-commercial plasma, yet it has not been shown to reduce the risk of complications. Thorough evaluation of the various plasma products and national guidelines for their use are warranted. In the absence of such guidelines, we recommend the non-commercial products for plasma treatment. SD plasma should primarily be considered to treat haemophilic patients, when specific factor based treatment is unavailable.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Blood Component Transfusion: contraindications, Blood Component Transfusion: adverse effects, Blood Component Transfusion: utilization
in
Läkartidningen
issue
1
pages
26 - 30
external identifiers
  • pmid:18293742
  • scopus:38549180559
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
630ab702-db02-4a30-a534-3cfc5ae3b045 (old id 1299104)
alternative location
http://ltarkiv.lakartidningen.se/artNo34464
date added to LUP
2009-07-09 14:05:07
date last changed
2017-07-27 07:33:28
@article{630ab702-db02-4a30-a534-3cfc5ae3b045,
  abstract     = {There are great regional variations in the use of plasma products. Evidence-based guidelines for plasma treatment are lacking. The Swedish market offers a non-commercial plasma product, produced by the hospital-based transfusion departments. There is also the commercial, virus-inactivated “SD plasma”. This is more expensive than the non-commercial plasma, yet it has not been shown to reduce the risk of complications. Thorough evaluation of the various plasma products and national guidelines for their use are warranted. In the absence of such guidelines, we recommend the non-commercial products for plasma treatment. SD plasma should primarily be considered to treat haemophilic patients, when specific factor based treatment is unavailable.},
  author       = {Palmblad, J and Johnsson, H and Lagerkranser, M and Sundelin, G and Wikman, A and Schött, Ulf},
  issn         = {0023-7205},
  keyword      = {Blood Component Transfusion: contraindications,Blood Component Transfusion: adverse effects,Blood Component Transfusion: utilization},
  language     = {swe},
  number       = {1},
  pages        = {26--30},
  series       = {Läkartidningen},
  title        = {Blodplasma används som läkemedel. Men nationella, evidensbaserade behandlingsriktlinjer saknas},
  year         = {2008},
}